Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of macitentan in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension
jRCT2051200150Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Macitentan with Placebo (2 arms). Primary endpoint: Change from baseline to Week 28 in 6-minute walk distance. Started Jul 2021; status: completed.
02
Drugs
macitentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on jRCT2051200150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200150.